ArticleOncotarget2018
Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 58 citations in OpenAlex.
- Pathological response and metabolites' prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial.Breast cancer research : BCR · 2025Trial
- Article
- Unveiling the anticancer potential of medicinal plants: metabolomics and analytical tools in phytomedicine.Molecular diversity · 2026Review
- Time-dependent memory of hypoxia exposure influences tumor invasion dynamics.bioRxiv : the preprint server for biology · 2026Article
- Mitochondrial biology and immune crosstalk in breast cancer: therapeutic opportunities and challenges.Frontiers in immunology · 2026Review
- Fucosylated N-Glycan Landscape of Triple-Negative Breast Cancer.Molecular cancer research : MCR · 2025Article
- Novel Aza-podophyllotoxin Derivative Inhibits Growth of Triple-Negative Breast Cancer.ACS omega · 2025Article
- Metabolomic Analysis of Breast Cancer in Colombian Patients: Exploring Molecular Signatures in Different Subtypes and Stages.International journal of molecular sciences · 2025Article
- Detecting Glutathione and Related Antioxidants as Biomarkers in Patient Breast Tumor Tissues: An Update in the Age of Metabolomics.Oxidative medicine and cellular longevity · 2025Review
- Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.Molecular cancer · 2024Review
- Article
- The potential of aryl hydrocarbon receptor as receptors for metabolic changes in tumors.Frontiers in oncology · 2024Review
- The Role of Amino Acids in the Diagnosis, Risk Assessment, and Treatment of Breast Cancer: A Review.Current issues in molecular biology · 2023Review
- Identification of metabolic pathways contributing to ERScientific reports · 2023Article
- The impact of lipid metabolism on breast cancer: a review about its role in tumorigenesis and immune escape.Cell communication and signaling : CCS · 2023Review
- G6PD activation in TNBC cells induces macrophage recruitment and M2 polarization to promote tumor progression.Cellular and molecular life sciences : CMLS · 2023Article
- NMR-Based Metabolomics to Evaluate Individual Response to Treatments.Handbook of experimental pharmacology · 2023Article
- Article
- Article
- Metabolomics of Breast Cancer: A Review.Metabolites · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
Abstract
Breast cancer, a heterogeneous disease with variable pathophysiology and biology, is classified into four major subtypes. While hormonal- and antibody-targeted therapies are effective in the patients with luminal and HER-2 subtypes, the patients with triple-negative breast cancer (TNBC) subtype do not benefit from these therapies. The incidence rates of TNBC subtype are higher in African-American women, and the evidence indicates that these women have worse prognosis compared to women of European descent. The reasons for this disparity remain unclear but are often attributed to TNBC biology. In this study, we performed metabolic analysis of breast tissues to identify how TNBC differs from luminal A breast cancer (LABC) subtypes within the African-American and Caucasian breast cancer patients, respectively. We used High-Resolution Magic Angle Spinning (HR-MAS) 1H Nuclear magnetic resonance (NMR) to perform the metabolomic analysis of breast cancer and adjacent normal tissues (total n=82 samples). TNBC and LABC subtypes in African American women exhibited different metabolic profiles. Metabolic profiles of these subtypes were also distinct from those revealed in Caucasian women. TNBC in African-American women expressed higher levels of glutathione, choline, and glutamine as well as profound metabolic alterations characterized by decreased mitochondrial respiration and increased glycolysis concomitant with decreased levels of ATP. TNBC in Caucasian women was associated with increased pyrimidine synthesis. These metabolic alterations could potentially be exploited as novel treatment targets for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.